TG Therapeutics is a commercial-stage biotechnology company that acquires, develops, and commercializes novel treatments for B-cell-mediated diseases, with a primary focus on multiple sclerosis. The company's lead product, BRIUMVI (ublituximab-xiiy), is an FDA-approved anti-CD20 monoclonal antibody for relapsing forms of multiple sclerosis administered as intravenous infusions, with commercial operations in the United States and Europe through partnership arrangements. TG generates revenue from direct U.S. sales of BRIUMVI and from licensing partnerships that provide upfront payments, milestone-based payments, and tiered royalties on net product sales, while advancing a pipeline of additional ublituximab formulations and an allogeneic CAR T cell therapy for progressive multiple sclerosis.